Hepatocyte Transplantation: Quo Vadis?

Research output: Contribution to journalReview article

Abstract

Orthotopic liver transplantation (OLT) has been effective in managing end-stage liver disease since the advent of cyclosporine immunosuppression therapy in 1980. The major limitations of OLT are organ supply, monetary cost, and the burden of lifelong immunosuppression. Hepatocyte transplantation, as a substitute for OLT, has been an exciting topic of investigation for several decades. HT is potentially minimally invasive and can serve as a vehicle for delivery of personalized medicine through autologous cell transplant after modification ex vivo. However, 3 major hurdles have prevented large-scale clinical application: (1) availability of transplantable cells; (2) safe and efficient ex vivo gene therapy methods; and (3) engraftment and repopulation efficiency. This review will discuss new sources for transplantable liver cells obtained by lineage reprogramming, clinically acceptable methods of genetic manipulation, and the development of hepatic irradiation–based preparative regimens for enhancing engraftment and repopulation of transplanted hepatocytes. We will also review the results of the first 3 patients with genetic liver disorders who underwent preparative hepatic irradiation before hepatocyte transplantation.

Original languageEnglish (US)
Pages (from-to)922-934
Number of pages13
JournalInternational Journal of Radiation Oncology Biology Physics
Volume103
Issue number4
DOIs
StatePublished - Mar 15 2019

Fingerprint

transplantation
liver
Hepatocytes
Transplantation
Liver Transplantation
Liver
immunosuppression
Immunosuppression
Precision Medicine
Inborn Genetic Diseases
End Stage Liver Disease
Autografts
Cell Lineage
cells
Genetic Therapy
Cyclosporine
gene therapy
Transplants
medicine
Costs and Cost Analysis

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Hepatocyte Transplantation : Quo Vadis? / Barahman, Mark; Asp, Patrik K.M.; Roy-Chowdhury, Namita; Kinkhabwala, Milan; Roy-Chowdhury, Jayanta; Kabarriti, Rafi; Guha, Chandan.

In: International Journal of Radiation Oncology Biology Physics, Vol. 103, No. 4, 15.03.2019, p. 922-934.

Research output: Contribution to journalReview article

@article{3e022334ef2545c8848c9fdc6f126dbc,
title = "Hepatocyte Transplantation: Quo Vadis?",
abstract = "Orthotopic liver transplantation (OLT) has been effective in managing end-stage liver disease since the advent of cyclosporine immunosuppression therapy in 1980. The major limitations of OLT are organ supply, monetary cost, and the burden of lifelong immunosuppression. Hepatocyte transplantation, as a substitute for OLT, has been an exciting topic of investigation for several decades. HT is potentially minimally invasive and can serve as a vehicle for delivery of personalized medicine through autologous cell transplant after modification ex vivo. However, 3 major hurdles have prevented large-scale clinical application: (1) availability of transplantable cells; (2) safe and efficient ex vivo gene therapy methods; and (3) engraftment and repopulation efficiency. This review will discuss new sources for transplantable liver cells obtained by lineage reprogramming, clinically acceptable methods of genetic manipulation, and the development of hepatic irradiation–based preparative regimens for enhancing engraftment and repopulation of transplanted hepatocytes. We will also review the results of the first 3 patients with genetic liver disorders who underwent preparative hepatic irradiation before hepatocyte transplantation.",
author = "Mark Barahman and Asp, {Patrik K.M.} and Namita Roy-Chowdhury and Milan Kinkhabwala and Jayanta Roy-Chowdhury and Rafi Kabarriti and Chandan Guha",
year = "2019",
month = "3",
day = "15",
doi = "10.1016/j.ijrobp.2018.11.016",
language = "English (US)",
volume = "103",
pages = "922--934",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Hepatocyte Transplantation

T2 - Quo Vadis?

AU - Barahman, Mark

AU - Asp, Patrik K.M.

AU - Roy-Chowdhury, Namita

AU - Kinkhabwala, Milan

AU - Roy-Chowdhury, Jayanta

AU - Kabarriti, Rafi

AU - Guha, Chandan

PY - 2019/3/15

Y1 - 2019/3/15

N2 - Orthotopic liver transplantation (OLT) has been effective in managing end-stage liver disease since the advent of cyclosporine immunosuppression therapy in 1980. The major limitations of OLT are organ supply, monetary cost, and the burden of lifelong immunosuppression. Hepatocyte transplantation, as a substitute for OLT, has been an exciting topic of investigation for several decades. HT is potentially minimally invasive and can serve as a vehicle for delivery of personalized medicine through autologous cell transplant after modification ex vivo. However, 3 major hurdles have prevented large-scale clinical application: (1) availability of transplantable cells; (2) safe and efficient ex vivo gene therapy methods; and (3) engraftment and repopulation efficiency. This review will discuss new sources for transplantable liver cells obtained by lineage reprogramming, clinically acceptable methods of genetic manipulation, and the development of hepatic irradiation–based preparative regimens for enhancing engraftment and repopulation of transplanted hepatocytes. We will also review the results of the first 3 patients with genetic liver disorders who underwent preparative hepatic irradiation before hepatocyte transplantation.

AB - Orthotopic liver transplantation (OLT) has been effective in managing end-stage liver disease since the advent of cyclosporine immunosuppression therapy in 1980. The major limitations of OLT are organ supply, monetary cost, and the burden of lifelong immunosuppression. Hepatocyte transplantation, as a substitute for OLT, has been an exciting topic of investigation for several decades. HT is potentially minimally invasive and can serve as a vehicle for delivery of personalized medicine through autologous cell transplant after modification ex vivo. However, 3 major hurdles have prevented large-scale clinical application: (1) availability of transplantable cells; (2) safe and efficient ex vivo gene therapy methods; and (3) engraftment and repopulation efficiency. This review will discuss new sources for transplantable liver cells obtained by lineage reprogramming, clinically acceptable methods of genetic manipulation, and the development of hepatic irradiation–based preparative regimens for enhancing engraftment and repopulation of transplanted hepatocytes. We will also review the results of the first 3 patients with genetic liver disorders who underwent preparative hepatic irradiation before hepatocyte transplantation.

UR - http://www.scopus.com/inward/record.url?scp=85061540877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061540877&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2018.11.016

DO - 10.1016/j.ijrobp.2018.11.016

M3 - Review article

VL - 103

SP - 922

EP - 934

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -